News

Russia claims successful human trials of COVID-19 vaccine

Garsha Sai Nitesh
Garsha Sai Nitesh
Covid 19 vaccine

Russia's Sechenov University claims it has successfully completed the world's first clinical trials of the COVID-19 vaccine on humans. Russia is one of the worst-hit nations with cases more than 7 lakh and daily case records touch 6,000.

Institute for Translational Medicine and Biotechnology Vadim Tarasov director confirmed the development related to the vaccine to Sputnik news.

"Sechenov University has successfully completed tests on volunteers of the world`s first vaccine against coronavirus," Tarasov said.

Gamalei Institute of Epidemiology and Microbiology in Russia produced the vaccine. The university started its clinical trials of the vaccine on June 18. Now the first group of volunteers who took the vaccine will be discharged on Wednesday and the second group on July 20.

"According to the data obtained by the Gamalei National Research Center for Epidemiology and Microbiology shows that volunteers of the first and second groups are complete normal and performing an immune response after injections of the vaccine against the coronavirus," Russian Defense Ministry said.

The director of the Institute of Medical Parasitology, Tropical and Vector-Borne Diseases at Sechenov University Alexander Lukashev said the safety of this vaccine is confirmed to be in correspondence to the safety of other medicines in the market.

Now Russia is the first country to successfully complete human trials of the vaccine and results shown the vaccine is effective. At present no information regarding the commercial launch of the vaccine is announced.

There are nearly 21 vaccines under the key trails around the world according to the WHO. In India, two vaccines are on the front runners of the race.

Like this article?

Hey! I am Garsha Sai Nitesh. Did you liked this article and have suggestions to improve this article? Mail me your suggestions and feedback.

Share your comments

Subscribe to our Newsletter. You choose the topics of your interest and we'll send you handpicked news and latest updates based on your choice.

Subscribe Newsletters